Every 8-K that RAPT Therapeutics, Inc. (RAPT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow RAPT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RAPT filings page.
RAPT Therapeutics, Inc. has been acquired by GlaxoSmithKline through a cash tender offer followed by a merger under Delaware law. GSK’s subsidiary purchased all outstanding RAPT common shares at $58.00 per share in cash, and approximately 30,137,567 shares, or 93.36% of outstanding shares, were validly tendered.
After completing the offer, GSK merged its acquisition vehicle into RAPT, making RAPT a direct wholly owned subsidiary. RAPT’s Nasdaq-listed common stock will be halted, delisted and deregistered, and the company plans to terminate its SEC reporting obligations. RAPT’s prior directors and officers resigned, and new GSK-affiliated officers and directors were appointed.
RAPT Therapeutics, Inc. entered into a definitive Agreement and Plan of Merger with GlaxoSmithKline LLC under which a GSK subsidiary will launch a cash tender offer to acquire all outstanding RAPT common shares at $58.00 per share, without interest and subject to withholding taxes. Completion of the offer is conditioned on a majority of RAPT shares being tendered and on required antitrust clearances under the HSR Act, among other customary conditions. After the offer closes, the buyer’s subsidiary will merge into RAPT, which will become a wholly owned GSK subsidiary, and remaining shares will receive the same cash price. The agreement includes a $78.4 million termination fee payable by RAPT in certain circumstances and a $100.8 million reverse termination fee payable by GSK if specified regulatory-related conditions are not met by the contractual end date.
RAPT Therapeutics, Inc. filed a current report to let investors know that the company will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company is providing its conference presentation as Exhibit 99.1, described as a corporate presentation, and making it available for transparency under Regulation FD, which governs fair disclosure of information to investors. The report also clarifies that the presentation and related information are being furnished rather than filed, meaning they are not subject to certain liability provisions of the securities laws and are not automatically incorporated into other SEC filings unless specifically referenced.
RAPT Therapeutics filed an 8‑K stating it furnished a press release announcing financial results for the quarter and nine months ended September 30, 2025. The release is included as Exhibit 99.1.
The company states the Item 2.02 information and Exhibit 99.1 are furnished, not filed, and are not incorporated by reference into other SEC filings.
RAPT Therapeutics announced an underwritten public offering of 8,333,334 shares of common stock at $30.00 per share. Underwriters will purchase shares at $28.20 each, and have a 30-day option to buy up to 1,250,000 additional shares.
The company estimates net proceeds of $234.4 million, or $269.7 million if the option is fully exercised. RAPT states that these proceeds, together with existing cash, cash equivalents and marketable securities, are expected to fund operations into 2028. Closing is expected on October 23, 2025, subject to customary conditions. The offering is being made under an effective Form S-3 and prospectus supplement.
RAPT Therapeutics (Nasdaq: RAPT) filed an 8-K reporting governance changes effective June 21 2025.
The Board expanded from five to seven directors and appointed Scott Braunstein, M.D. and Ashley Dombkowski, Ph.D. as Class III directors, with terms running through the 2028 annual meeting. Dr. Braunstein joins the Audit Committee, while Dr. Dombkowski joins the Nominating & Corporate Governance Committee.
The filing also notes an amendment to the non-employee director compensation policy; new directors now receive a one-time option grant for 25,000 common shares. Both directors executed standard indemnification agreements, and the company states that no related-party transactions exist under Item 404(a).